NASDAQ$DVAX

Dynavax Technologies Corp · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Dynavax reported second quarter 2023 financial results, highlighted by record HEPLISAV-B vaccine revenue and raised full-year revenue guidance.

Dynavax reported total revenues of $60.2 million for the second quarter of 2023, including record HEPLISAV-B vaccine net product revenue of $56.4 million, a 73% year-over-year increase. The company raised its full year HEPLISAV-B net product revenue guidance to $200 - $215 million. Cash and investments increased to $682 million at quarter end.

  • Generated record quarterly HEPLISAV-B® vaccine net product revenue of $56 million, a 73% year-over-year increase
  • Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compared to prior range of $165 - $185 million
  • Cash and investments increased to $682 million at quarter end; expects positive free cash flow for full year
  • HEPLISAV-B total market share increased to approximately 39%, compared to approximately 32% at the end of the second quarter of 2022.

Headline financials

Total Revenue

$58.7M

Previous: $255M-77.0%
EPS (adj)

$0.03

Previous: $0.87-96.6%
HEPLISAV-B Market Share (US)

39.0%

Previous: 32.0%+21.9%
Capital Expenditures

-$2.03M

Previous: -$4.27M+52.4%
Free Cash Flow

$53.6M

Previous: -$38.1M+240.9%
Net Income

$3.43M

Previous: $129M-97.3%
Operating Income

-$3.41M

Previous: $128M-102.7%
Gross Profit

$45.2M

Previous: $172M-73.7%
Cash & Equivalents

$682M

Previous: $518M+31.5%
Total Assets

$936M

Previous: $1.02B-8.5%
Stock-Based Comp

$10.6M

Previous: $7.93M+33.2%

Revenue & EPS history

Dynavax · Revenue · Quarterly

$58.7M

Q2 2023-77%vs Q2 2022
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Dynavax · $3.8M total across 1 segment · Q2 2023

  • Other Revenue
    $3.8M

Forward guidance

Dynavax revised its full year 2023 financial guidance.

Tailwinds

  • Raising HEPLISAV-B net product revenue between approximately $200 - $215 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 16 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

-0.6%

Avg return

Earnings day

+1.2%

Avg return

5 days after

+0.9%

Avg return

30 days after

49%

31 / 63 earnings

Positive

+18.1%

Q1 2019

Best reaction

-29.1%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025-1.5%+2.4%-1.0%
Q2 2025-6.7%-2.2%-9.0%
Q1 2025-11.0%-9.6%-6.1%
Q4 2024+0.0%+2.5%+3.6%
Q3 2024+5.9%+9.6%+4.5%
Q2 2024+6.8%+10.1%+7.2%
Q1 2024-6.4%-6.2%+2.6%
Q4 2023+2.3%+4.3%-1.4%
Q3 2023+0.9%-5.5%-2.8%
Q2 2023+7.1%+10.0%+7.4%
Q1 2023+4.8%+7.0%+9.0%
Q4 2022-5.0%-5.5%-9.4%
Q3 2022+11.6%+10.3%+12.6%
Q2 2022+17.8%+20.7%-20.6%
Q1 2022-4.3%-12.0%+29.7%
Q4 2021-2.2%-16.1%-11.8%
Q3 2021-22.8%
Q2 2021+6.1%
Q1 2021+9.7%
Q4 2020-6.7%
Q3 2020+0.5%
Q2 2020-13.5%
Q1 2020-8.8%
Q4 2019-29.1%
Q3 2019-5.4%
Q2 2019+5.2%
Q1 2019+18.1%
Q4 2018-7.8%
Q3 2018+2.2%
Q2 2018+5.8%
Q1 2018-5.0%
Q4 2017-0.3%
Q3 2017+6.4%
Q2 2017+12.7%
Q1 2017+0.9%
Q4 2016-2.5%
Q3 2016+6.7%
Q2 2016-2.3%
Q1 2016+8.7%
Q4 2015-4.6%
Q3 2015-1.5%
Q2 2015+10.8%
Q1 2015+1.9%
Q4 2014+0.1%
Q3 2014-1.9%
Q2 2014-9.2%
Q1 2014-3.9%
Q4 2013-4.2%
Q3 2013+4.5%
Q2 2013+2.4%
Q1 2013-5.2%
Q4 2012+2.1%
Q3 2012+0.5%
Q2 2012+2.4%
Q1 2012-3.6%
Q4 2011+3.1%
Q3 2011-14.0%
Q2 2011-14.6%
Q1 2011-1.1%
Q4 2010-2.5%
Q3 2010+2.4%
Q2 2010-8.1%
Q1 2010+7.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro